Reviva Pharmaceuticals Holdings said on Monday its lead experimental drug to treat adults with schizophrenia helped reduce disease symptoms in a late-stage study. Schizophrenia is a chronic mental disorder that causes distortion in thoughts, hallucinations and feelings of fright and paranoia.
The drug, brilaroxazine, clocked a 10.1 point reduction, compared to a placebo, in a medical scale used to measure the severity of schizophrenia symptoms like delusions, hallucinations and emotional withdrawal among others.
Brilaroxazine belongs to a class of drugs called serotonin-dopamine signaling modulator which regulates the levels of two chemical messengers in the brain, serotonin and dopamine.
https://finance.yahoo.com/news/1-reviva-pharmas-schizophrenia-drug-115439723.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.